Brief: Medicenna To Present Pre-clinical Data On MDNA19

Medicenna Therapeutics

25/03/2020 11:43

March 25 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA'S IL-2 SUPERKINE, MDNA19, DEMONSTRATES
BEST-IN-CLASS
FEATURES IN A NON-HUMAN PRIMATE STUDY
    * MEDICENNA - KINETIC STUDIES IN NHP SHOWED DOSE-DEPENDENT
UPREGULATION OF KI67 IN CD8 T-CELLS LASTING FOR ALMOST 2 WEEKS
POST-MDNA19 ADMINISTRATION
    * MEDICENNA THERAPEUTICS CORP - SUCCESSFULLY CLOSED A $35
MILLION
FINANCING LAST WEEK

Source text for Eikon:  ID:nPn8WPqJTa 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))